Gland Pharma stock gains after bulk deal lifts sentiment

Published on 09/18/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gland Pharma stock traded at INR 2,900.00 on the NSE on September 18, 2026, about 4.7 percent below its 52-week high of INR 3,042.00. A recent bulk deal involving 150,000 shares has highlighted renewed institutional interest in the company.

Gland Pharma, INE025W01027, Illustration mit AI erstellt.

Gland Pharma stock (ISIN INE025W01027) traded at INR 2,900.00 on the National Stock Exchange of India on September 18, 2026, leaving the shares about 4.7 percent below their 52-week high of INR 3,042.00 as investors weighed fresh institutional buying interest. According to NDTV Profit on September 18, 2026, a bulk deal in Gland Pharma shares has drawn attention to the stock.

Bulk deal puts Gland Pharma stock in focus

As NDTV Profit reported on September 18, 2026, BOFA Securities Europe SA bought 150,000 Gland Pharma shares at INR 2,826.60 per share in a bulk deal, while North Rock SG VCC sold an identical number of shares at the same price. The transaction value was around INR 424 million, underlining meaningful institutional interest at a level slightly below the latest closing price.

The impact of this liquidity event has been visible in the stock performance. According to live equity data from the National Stock Exchange of India as of September 18, 2026, Gland Pharma opened at INR 2,827.90, hit an intraday high of INR 2,941.10 and a low of INR 2,820.10 before last trading at INR 2,900.00, implying a gain of 2.6 percent versus the previous close of INR 2,826.60 and placing the price between the 52-week low of INR 1,573.60 and the 52-week high of INR 3,042.00 for the same as-of date. The same NSE data show trading volume of 678,985 shares on this session and a total traded value of INR 1,972.3 million, indicating elevated activity compared with quieter periods.

Recent performance within the Nifty Pharma index

The broader sector context has also supported Gland Pharma stock. As Business Standard reported on September 17, 2026, the Nifty Pharma index rose 1.66 percent on that session, with Gland Pharma shares jumping 2.87 percent alongside gains in Alkem Laboratories and Dr Reddys Laboratories. This move aligned Gland Pharma stock with a broader positive trend in Indian pharmaceutical names, even as individual company-specific news remained limited in the week.

Valuation metrics from a Nifty 500 overview dated September 17, 2026 indicate that Gland Pharma had a market capitalization of INR 466.85 billion and a trailing price-to-earnings ratio of 41.36, based on a trailing earnings yield of 2.42 percent at a reference price of INR 2,911.00. According to this same overview, the stock delivered a 30-day performance of 10.05 percent, significantly outpacing broader benchmark indices over the same period and underlining how strongly the shares have recovered from their 52-week low of INR 1,575.00 recorded on March 16, 2026. The distance between the latest price of INR 2,900.00 and that 52-week low corresponds to a gain of about 84 percent over that timeframe.

Fundamental backdrop and investor takeaway

While no new quarterly or annual figures were released in the last few days, the current trading range reflects the market’s view on Gland Pharma’s most recently reported fundamentals in the injectable and contract manufacturing business. A Nifty 500 stock list updated on September 17, 2026 characterizes the company as part of the healthcare and pharmaceuticals segment and shows that, at a price near INR 2,911.00, key valuation metrics such as a price-to-book ratio of 4.39 and a return on equity of 13.18 percent frame investor expectations about future growth and profitability. These figures suggest that the market is willing to assign a premium multiple relative to some more mature peers, given double-digit returns on equity.

The same data set also highlights that Gland Pharma’s free-float liquidity and institutional participation support active trading. The 52-week high of INR 3,042.00 was set on September 7, 2026, only about ten days before the latest close, so the current price of INR 2,900.00 leaves the stock roughly 4.7 percent below that peak while still far above the 52-week low. For investors, this combination of strong recovery from the low, modest pullback from the high and fresh bulk buying by a global bank creates a technically interesting zone in which new information about earnings, regulatory approvals or capacity additions could quickly shift sentiment.

Gland Pharma stock price and key data

As of the close on September 18, 2026, Gland Pharma stock traded at INR 2,900.00 on the National Stock Exchange of India, up 2.6 percent from the previous close of INR 2,826.60, with intraday trading between INR 2,820.10 and INR 2,941.10 and a 52-week range from INR 1,573.60 to INR 3,042.00. For the same date, a Nifty 500 overview indicates a market capitalization near INR 466.85 billion, underlining the company’s position in the Indian mid- to large-cap pharmaceutical universe.